恒瑞医药与美国Braveheart Bio签署HRS-1893项目授权许可协议

Group 1 - Company Heng Rui Medicine (600276.SH) has entered into an agreement with Braveheart Bio, Inc. to license its innovative drug HRS-1893, which has independent intellectual property rights [1] - The licensing agreement grants Braveheart Bio exclusive rights to develop, produce, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1] - Braveheart Bio will pay a total of $75 million to Heng Rui, which includes a $65 million upfront payment and a $10 million milestone payment upon completion of technology transfer [1] Group 2 - HRS-1893 is a myosin selective inhibitor that works by inhibiting the activity of cardiac myosin ATPase, thereby reducing excessive myocardial contraction, decreasing left ventricular hypertrophy, and improving diastolic relaxation [2] - The drug is currently in Phase III clinical development for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) [2]